1. FDA Committee Votes 6-6 on Durect's Non-Opioid Pain Drug — Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 — Novo Nordisk's Ozempic wins FDA label boost with CV indication — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Oh a guidewire

Discussion in 'Vascular Solutions' started by Anonymous, Dec 13, 2009 at 2:00 PM.

  1. Anonymous

    Anonymous Guest

    What a joke this company is. I interviewed with the Sr. Director of US Sales. The guy is affraid of his own shadow. Plus he runs the business like a pharm rep. Reports after report of what you were or are doing in the field. I said no thanks after meeting this tool.
     
  2. Anonymous

    Anonymous Guest

    LMAO! I love it. I had a similar experience. When asked my strengths, I gave pretty solid answers. Weakness, PAPERWORK! I sell! If I wanted to do reports all day I certainly would not have chosen this as my career!
     
  3. Anonymous

    Anonymous Guest

    Me too!!! I'm so glad I turned them down. Just didn't seem right. Now after talking to some Doc's, I'm really glad I didn't take this job!!!!
     
  4. Anonymous

    Anonymous Guest

    HA! Nice to see you guys blew them off...great job staying off that sinking ship!